Mpex Reports Positive Results From Phase 2b Clinical Trial With Aeroquin

Mpex Pharmaceuticals (Mpex) has reported positive top line results from a phase 2b clinical trial with Aeroquin, a new aerosol formulation of levofloxacin delivered by an optimised Investigational eFlow Nebulizer System from PARI Pharma.

Reportedly, in the Mpex cystic fibrosis trial, nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa in sputum after 28 days of dosing versus placebo.

Mpex has reported that clinically and statistically significant improvements versus placebo were also seen in a number of important clinical endpoints, including FEV1, % predicted FEV1, FEF25-75 and time to need for anti-pseudomonal antibiotics (a measure of exacerbations).

Martin Knoch, president of PARI Pharma, said: “It is exciting to see these positive results with Mpex’s Aeroquin delivered by an optimised Investigational eFlow Nebulizer System. We are seeing a variety of studies showing great results when inhaled medications are optimised for delivery with a customised Investigational eFlow Nebulizer System. This is good news for cystic fibrosis patients and their care givers.”